Does Lexapro cause hair loss? This is a question raised by some patients prescribed escitalopram (sold as Cipralex in the UK), a widely used SSRI antidepressant for depression and anxiety. Hair loss — medically termed alopecia — is listed as an adverse effect in escitalopram's prescribing information, though it is considered uncommon. The type most frequently associated with SSRIs is telogen effluvium, a temporary, diffuse shedding that is often reversible. This article explores the evidence, explains why it happens, and outlines practical steps to take if you notice hair thinning whilst taking escitalopram.

Can Escitalopram (Cipralex) Cause Hair Loss?

Escitalopram can cause hair loss, listed as an adverse effect in its SmPC; the most common type is telogen effluvium — temporary, diffuse shedding that is often reversible rather than permanent.

Experiencing these side effects? Our pharmacists can help you navigate them →

Escitalopram, sold under the brand name Cipralex in the UK (Lexapro is the US brand name), is a selective serotonin reuptake inhibitor (SSRI) widely prescribed for depression and anxiety disorders. One question that patients sometimes raise is whether this medication can contribute to hair loss — a concern that is understandable given how distressing changes in hair density can be.

Hair loss (medically termed alopecia) has been reported as an adverse effect in the Summary of Product Characteristics (SmPC) for Cipralex (escitalopram); patients should consult the current UK SmPC on the Electronic Medicines Compendium (emc) or the NHS Medicines A–Z page for escitalopram for the exact frequency categorisation, as product labelling is periodically updated. The European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) acknowledge this association, though a listed side effect does not automatically mean the drug is the definitive cause in every individual case.

The type of hair loss most commonly associated with SSRIs is telogen effluvium — a temporary, diffuse shedding of hair rather than patchy or permanent loss. This occurs when hair follicles are prematurely pushed into the resting (telogen) phase of the growth cycle. Importantly, this form of hair loss is often reversible once the triggering factor is addressed. Patients should be reassured that, for the vast majority of people taking escitalopram, hair loss is not a reported concern, and there is no established causal mechanism that makes it an expected or inevitable outcome of treatment.

How Common Is Hair Loss With Antidepressants in the UK?

Hair loss is classified as an uncommon to rare side effect of SSRIs; it typically begins 2–4 months after starting treatment and often resolves within 6–12 months, even without stopping the medication.

Not sure if this is normal? Chat with one of our pharmacists →

Across the class of SSRI antidepressants — which includes fluoxetine, sertraline, citalopram, and escitalopram — hair loss is listed as an uncommon to rare adverse effect depending on the specific medicine; frequency categories differ between products, so individual SmPCs should be consulted rather than assuming a uniform class-wide rate.

The MHRA's Yellow Card spontaneous reporting scheme does include reports of alopecia associated with SSRIs. However, it is important to note that spontaneous adverse event reports cannot be used to estimate the true frequency of a side effect, owing to well-recognised under-reporting and reporting bias. Yellow Card data is valuable for signal detection, not for calculating incidence.

It is also worth considering that hair loss itself is extremely prevalent in the general population, affecting both men and women for a wide variety of reasons — including stress, nutritional deficiencies, thyroid disorders, hormonal changes, and genetic predisposition. When someone begins an antidepressant, they may simultaneously be experiencing significant psychological stress, which is itself a well-recognised trigger for telogen effluvium. This makes it genuinely difficult to attribute hair shedding solely to the medication.

Based on published case reports and post-marketing data, telogen effluvium linked to SSRIs typically begins approximately 2–4 months after starting the drug, and hair regrowth often occurs within 6–12 months, even if the medication is continued — though this can vary and persistence is possible if the underlying trigger is ongoing. These timelines are consistent with the recognised natural history of telogen effluvium as described in UK dermatology guidance from the British Association of Dermatologists (BAD) and the Primary Care Dermatology Society (PCDS).

Overall, the available evidence does not support hair loss as a common or predictable consequence of taking escitalopram, though individual susceptibility can vary.

Why Some Medicines Affect Hair Growth

SSRIs may trigger telogen effluvium by prematurely shifting hair follicles into the resting phase, possibly via serotonergic effects on follicle cycling or modest hormonal changes, though the exact mechanism remains unclear.

To understand why certain medications might influence hair growth, it helps to appreciate the normal hair cycle. Hair follicles cycle through three phases: anagen (active growth, lasting 2–6 years), catagen (transition, lasting a few weeks), and telogen (resting and shedding, lasting around 3 months). At any given time, approximately 85–90% of scalp hairs are in the anagen phase.

Drug-induced hair loss most commonly takes the form of telogen effluvium, where a physiological or pharmacological stressor causes a disproportionate number of follicles to enter the telogen phase simultaneously. The result is diffuse shedding, typically noticed 2–4 months after the triggering event — which is why patients may not immediately connect hair loss to a medication they started several months earlier.

The precise mechanism by which SSRIs such as escitalopram might trigger this process is not fully understood. Several hypotheses have been proposed, though none is conclusively established:

• Serotonergic effects on follicle cycling: Serotonin receptors are present in hair follicles, and it has been hypothesised that altered serotonin signalling may influence the timing of follicle phase transitions

• Hormonal interactions: SSRIs can modestly affect prolactin levels, which in turn may theoretically influence hair growth cycles

• Lag effect of a physiological stressor: As with other recognised triggers of telogen effluvium (such as illness, surgery, or significant stress), any physiological change associated with starting a new medicine may shift follicles into the telogen phase, with shedding apparent only months later

Given the speculative nature of these mechanisms, it is most accurate to say that the biological basis for SSRI-related telogen effluvium remains incompletely understood. It is also worth noting that untreated depression and chronic stress are independently associated with hair loss, meaning the underlying condition — rather than its treatment — may sometimes be the primary driver.

What to Do If You Notice Hair Thinning on Escitalopram

Do not stop escitalopram abruptly; speak to your GP, keep a record of shedding, and ask about initial blood tests including FBC, serum ferritin, and TSH to rule out other causes.

If you notice increased hair shedding or thinning after starting escitalopram, it is important not to panic or stop your medication abruptly. Stopping an SSRI suddenly can cause discontinuation symptoms — including dizziness, nausea, irritability, and flu-like sensations — and should always be done under medical supervision with a gradual tapering plan.

Instead, consider the following practical steps:

• Keep a record: Note when the hair loss started, how much shedding you are noticing (e.g., on your pillow, in the shower), and any other changes in your health or lifestyle around the same time

• Review other potential causes: Consider whether you have experienced significant stress, dietary changes, weight loss, or illness recently, as these are common triggers for telogen effluvium independent of medication

• Speak to your GP about investigations: Your GP will guide which tests are appropriate based on your history and examination. In UK primary care, commonly considered initial investigations include a full blood count (FBC), serum ferritin, and thyroid-stimulating hormone (TSH). Tests such as vitamin B12, vitamin D, and zinc may be checked selectively if there is a clinical reason to suspect deficiency

• Be gentle with your hair: Avoid excessive heat styling, tight hairstyles, or harsh chemical treatments while shedding is occurring, as these can worsen breakage

In most cases, drug-related telogen effluvium is self-limiting. Hair density typically begins to recover within several months, even without any change to the medication.

Seek prompt medical review if you notice any of the following red flags:

• Rapid or marked hair loss

• Patchy rather than diffuse shedding

• Signs of scalp inflammation — such as redness, scaling, pain, or pustules — which may suggest a scarring alopecia requiring urgent assessment

• Associated systemic symptoms such as significant fatigue, unexplained weight change, or skin changes

These features may indicate an underlying condition such as thyroid dysfunction, autoimmune alopecia, or another dermatological diagnosis that warrants specialist evaluation.

Speaking to Your GP or Pharmacist About Side Effects

Your GP or pharmacist can assess whether escitalopram is the likely cause of hair loss, arrange relevant investigations, and discuss switching antidepressants if the side effect is causing significant distress.

Open communication with your healthcare team is essential when managing any side effect, including hair loss. Your GP or pharmacist can help determine whether escitalopram is the likely cause, or whether another explanation is more plausible. They can also arrange appropriate investigations and, if necessary, discuss alternative treatment options.

When you speak to your GP, it may be helpful to mention:

• The timeline of hair loss in relation to starting escitalopram

• Any previous episodes of hair loss

• Your current diet and any recent significant stressors

• Other medications or supplements you are taking, as some (including anticoagulants, retinoids, and certain hormonal treatments) are also associated with hair loss

Your GP may request blood tests to rule out thyroid disease, anaemia, iron deficiency, or other relevant conditions. If the hair loss appears to be medication-related and is causing significant distress, they may consider switching to an alternative antidepressant — though it is worth noting that hair loss has been reported, albeit uncommonly, across multiple antidepressant classes.

Pharmacists are also an excellent first point of contact. As medicines experts, they can review your full medication list for potential interactions or overlapping side effects, and advise on whether a GP appointment is warranted.

Any suspected adverse drug reaction can be reported directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Patient-reported Yellow Cards are welcomed and taken seriously by regulators, and help build the national evidence base for drug safety monitoring.

If at any point you experience thoughts of self-harm or suicide — whether related to your mental health condition or to concerns about your medication — contact your GP urgently, call NHS 111, or in an emergency dial 999.

Weighing the Benefits and Risks of Continuing Treatment

For most people, escitalopram's benefits for depression and anxiety substantially outweigh the small, often reversible risk of hair loss; treatment decisions should always be made collaboratively with your GP.

For most people prescribed escitalopram, the therapeutic benefits — reduced symptoms of depression or anxiety, improved quality of life, and better day-to-day functioning — substantially outweigh the small risk of experiencing hair loss. NICE guideline NG222 (Depression in adults: treatment and management, 2022) positions SSRIs as a first-line pharmacological option for depression when medication is clinically indicated, whilst also emphasising that non-pharmacological approaches (such as psychological therapies) are often appropriate first-line options for less severe depression. NICE guideline CG113 (Generalised anxiety disorder and panic disorder in adults) similarly supports SSRIs as a first-line pharmacological treatment for generalised anxiety disorder. Both guidelines reflect a strong evidence base for the efficacy and generally favourable tolerability profile of this drug class.

It is important to contextualise hair loss within the broader picture of your mental health treatment. Undertreated or untreated depression carries significant risks, including impaired social and occupational functioning, physical health consequences, and in severe cases, risk of self-harm. A reported but uncommon and often reversible side effect, while genuinely distressing, should be weighed carefully against these considerations.

That said, patient autonomy and quality of life matter. If hair loss is causing significant psychological distress — particularly in someone already managing a mental health condition — this is a valid clinical concern that deserves a thoughtful, individualised response from your healthcare team. Options may include:

• Watchful waiting, with reassurance that shedding is likely temporary

• Optimising nutritional status to support hair regrowth, guided by blood test results

• Switching antidepressants, if clinically appropriate and done gradually under medical supervision

• Referral to a dermatologist, if alopecia is persistent, rapidly progressive, patchy, or atypical

Ultimately, decisions about continuing, adjusting, or changing treatment should always be made collaboratively between you and your GP, taking into account your mental health needs, personal preferences, and the full clinical picture. Never stop escitalopram without medical guidance.

Frequently Asked Questions